Recently, the protective effect of several classes of anti-diabetic agents in cancer development and progression, especially metformin and thiazolidinedione, has been emphasized.[33, 34] On the contrary, insulin analogue seems to have mitogenic effects.[35] Therefore, choice of glucose lowering drugs may have its own role in affecting the outcome of HCC patients. Here, INS is linked to hepatocellular carcinoma.